Bellicum Pharma terminates CEO Richard Fair and CDO Charity Scripture; effective June 30, 2023

BELLICUM PHARMACEUTICALS, INC

CEO Richard Fair and CDO Charity Scripture notified on May 31 that employment ends June 30, 2023.
Both receive severance per agreements; Scripture gets COBRA reimbursement for up to 12 months.
Both will sign consulting agreements to continue as officers as consultants on hourly basis.
Severance conditioned on providing a general release of claims for the company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Richard Fair

President and Chief Executive Officer

BELLICUM PHARMACEUTICALS, INC

Effective: 2023-06-30
Filed: June 2, 2023, 7:59 PM ET

On May 31, 2023, the Company provided notices to Richard Fair, President and Chief Executive Officer, and Charity Scripture, Chief Development Officer that their employment by the Company will terminate on June 30, 2023.

Departed

Charity Scripture

Chief Development Officer

BELLICUM PHARMACEUTICALS, INC

Effective: 2023-06-30
Filed: June 2, 2023, 7:59 PM ET

On May 31, 2023, the Company provided notices to Richard Fair, President and Chief Executive Officer, and Charity Scripture, Chief Development Officer that their employment by the Company will terminate on June 30, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Richard Fair was terminated as President and Chief Executive Officer at BELLICUM PHARMACEUTICALS, INC.

Action: terminated
Role: President and Chief Executive Officer

Exact text from the filing

On May 31, 2023, the Company provided notices to Richard Fair, President and Chief Executive Officer, and Charity Scripture, Chief Development Officer that their employment by the Company will terminate on June 30, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Charity Scripture was terminated as Chief Development Officer at BELLICUM PHARMACEUTICALS, INC.

Action: terminated
Role: Chief Development Officer

Exact text from the filing

On May 31, 2023, the Company provided notices to Richard Fair, President and Chief Executive Officer, and Charity Scripture, Chief Development Officer that their employment by the Company will terminate on June 30, 2023.

View on SEC.gov

Source: SEC EDGAR

accession 0001628280-23-020619

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.